Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

20.0%

1 terminated/withdrawn out of 5 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
4(80.0%)
Phase 1
1(20.0%)
5Total
Phase 2(4)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT00308919Phase 2Completed

Study of Photodynamic Therapy in Patients With Prostate Cancer Following Radiation Therapy

Role: lead

NCT00305929Phase 2Completed

Study of WST09 in Prostate Cancer After Radiation: Repeat Procedure

Role: lead

NCT00312442Phase 2Terminated

Phase II/III Study of WST09 in Prostate Cancer After Radiation Therapy

Role: lead

NCT00284908Phase 1Completed

Dose-Effect of S-Tenatoprazole-Na(STU-Na) 30 mg, 60 mg, 90 mg and 120 mg in Healthy Volunteers

Role: lead

NCT00282555Phase 2Suspended

Efficiency Study of S-Tenatoprazole-Na to Treat Erosive or Ulcerative Esophagitis

Role: lead

All 5 trials loaded